Table 1:
Basic clinical and pathological data from the five patients who completed the study a.
| Patient | Sex | Age at enrollment | Race | Initial diagnosis | Tumor location | Tumor volume | IDH1 status | MGMT promoter methylation | Survival from enrollment (months) |
|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | M | 34 | Caucasian | Anaplastic astrocytoma Grade III b | R, Frontal | 1.9 mL | wt | Unmethylated | 12 |
| Patient 2 | F | 58 | Caucasian | GBM, IDH-wildtype | R, Temporal | 12.9 mL | wt | Unmethylated | 17 |
| Patient 3 | M | 61 | Caucasian | GBM, IDH-wildtype | L, Frontal | 5.1 mL | wt | Methylated | 10 |
| Patient 4 | M | 56 | Caucasian | GBM, IDH-wildtype | R, Temporal | 18.0 mL | wt | Unmethylated | 5 |
| Patient 5 | F | 51 | Caucasian | GBM, IDH-wildtype | R, Frontal | 4.1 mL | wt | Methylated | 25 |
a
See Supplemental Table S1A (webappendix page 12) for more information.
b
At recurrence, this patient’s tumor showed histopathological and molecular features diagnostic for GBM, IDH-wildtype